https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Kala_Pharmaceuticals%2C_Inc.Kala Pharmaceuticals, Inc. - Revizia istoricului2026-04-03T17:51:20ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Kala_Pharmaceuticals,_Inc.&diff=426977&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Kala Pharmaceuticals, Inc. listata cu simbolul US.KALA ==Descriere companie== Kala Pharmaceuticals, Inc. (https://www.kalarx.com/) is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for diseases of the eye. The Company's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS (...2024-09-18T18:07:13Z<p>Pagină nouă: Pagina dedicata companiei Kala Pharmaceuticals, Inc. listata cu simbolul US.KALA ==Descriere companie== Kala Pharmaceuticals, Inc. (https://www.kalarx.com/) is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for diseases of the eye. The Company's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS (...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Kala Pharmaceuticals, Inc. listata cu simbolul US.KALA<br />
<br />
==Descriere companie==<br />
Kala Pharmaceuticals, Inc. (https://www.kalarx.com/) is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for diseases of the eye. The Company's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, is a short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. INVELTYS (loteprednol etabonate ophthalmic suspension) 1%, is a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. The Company's AMPPLIFY technology uses selectively-sized nanoparticles that each have a proprietary coating. Its Preclinical Development Programs include rTKI Program for Retinal Diseases (KPI-285/KPI-286), SEGRM Program and Surface Targeted Steroid Program (KPI-333).<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.KALA" /><br />
<br />
==Ultimele stiri despre Kala Pharmaceuticals, Inc. (US.KALA)==<br />
<dynamicpagelist><br />
category=US.KALA<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.KALA]][[Categorie:Stiri despre companii]]</div>Admin